Myasthenia Gravis Misdiagnosis and Treatment Failures: An Attorney's Guide to Neuromuscular Malpractice Litigation
# Myasthenia Gravis Misdiagnosis and Treatment Failures: An Attorney's Guide to Neuromuscular Malpractice Litigation
Myasthenia gravis (MG) is an autoimmune neuromuscular disorder that causes fluctuating muscle weakness, and when misdiagnosed or improperly managed, can result in life-threatening respiratory failure, prolonged disability, and death. For attorneys handling medical malpractice and personal injury cases involving myasthenia gravis, understanding the clinical presentation, accepted diagnostic pathways, and well-established treatment protocols is essential to evaluating liability and building a persuasive case theory.
MG affects approximately 20 per 100,000 people in the United States, with a bimodal age distribution — younger women and older men are disproportionately affected. Despite being one of the best-understood autoimmune diseases in medicine, diagnostic delays remain common. Published studies report average delays of one to two years between symptom onset and definitive diagnosis, and some patients cycle through multiple incorrect diagnoses before MG is recognized. These delays create a fertile ground for malpractice claims, particularly when the patient deteriorates into myasthenic crisis during the period of missed or incorrect diagnosis.
Clinical Presentation and the Diagnostic Standard of Care
The hallmark of myasthenia gravis is fatigable weakness — muscle strength that worsens with repeated use and improves with rest. This distinguishing feature separates MG from most other neurological conditions and, when properly recognized, should prompt a focused diagnostic workup. The most common initial presentations include ptosis (drooping of one or both eyelids), diplopia (double vision), bulbar symptoms such as difficulty swallowing or slurred speech, and proximal limb weakness.
The standard of care for evaluating suspected myasthenia gravis is well-defined in neurological practice guidelines. When a patient presents with fluctuating weakness — particularly ocular or bulbar symptoms — the evaluating physician should include MG in the differential diagnosis and pursue appropriate testing. The accepted diagnostic workup includes serological testing for acetylcholine receptor (AChR) antibodies, which are positive in approximately 85% of generalized MG patients, and muscle-specific kinase (MuSK) antibodies, which account for a significant portion of AChR-seronegative cases. Electrodiagnostic testing, specifically repetitive nerve stimulation (RNS) and single-fiber electromyography (SFEMG), provides physiological confirmation of the neuromuscular junction defect.
Malpractice liability arises most commonly in three diagnostic failure scenarios. First, the physician fails to consider MG in the differential diagnosis at all, attributing the patient's symptoms to psychogenic disease, fatigue, depression, or normal aging. This is particularly common in emergency departments and primary care settings, where fluctuating ocular symptoms may be dismissed as benign. Second, the physician considers MG but orders only AChR antibody testing, which misses the 10-15% of generalized MG patients who are seronegative for AChR antibodies — failing to pursue MuSK antibody testing or electrodiagnostic studies represents a deviation from the accepted diagnostic algorithm. Third, the physician obtains a false-negative antibody result and inappropriately rules out MG without pursuing confirmatory electrodiagnostic testing, despite ongoing clinical suspicion.
In each of these scenarios, the expert witness analysis turns on whether the clinical presentation contained sufficient features to trigger an MG-directed evaluation, and whether the physician's response to those features met the standard of care in the relevant specialty. A neurologist evaluating these records will look for documented complaints of fluctuating weakness, ocular symptoms, swallowing difficulty, or voice changes — any of which, in the appropriate clinical context, should have prompted serological and electrodiagnostic evaluation.
Myasthenic Crisis: The Highest-Stakes Failure Mode
Myasthenic crisis is the most dangerous complication of myasthenia gravis, defined as respiratory failure requiring mechanical ventilation due to weakness of the diaphragm and accessory respiratory muscles. Approximately 15-20% of MG patients will experience at least one crisis during their disease course. Myasthenic crisis carries a mortality rate of approximately 4-8% even with modern intensive care, and survivors frequently experience prolonged ventilator dependence, ICU-acquired weakness, and lasting functional impairment.
From a liability perspective, myasthenic crisis cases present two distinct failure patterns. The first involves patients with known MG who develop crisis due to inadequate outpatient management — insufficient immunosuppressive therapy, failure to monitor respiratory function during exacerbations, inappropriate prescribing of medications known to exacerbate MG (aminoglycosides, fluoroquinolones, beta-blockers, magnesium, and certain anesthetic agents), or failure to recognize and treat early warning signs of impending respiratory compromise.
The second and often more devastating failure pattern involves patients who present to emergency departments in myasthenic crisis without a prior MG diagnosis. These patients frequently present with acute respiratory distress, progressive bulbar dysfunction, or generalized weakness, and the failure to recognize the neuromuscular etiology of the respiratory failure leads to delays in initiating appropriate treatment. Instead of receiving plasma exchange or intravenous immunoglobulin (IVIG) — the accepted acute treatments for crisis — these patients may be treated only with standard respiratory support while the underlying autoimmune process continues unchecked.
The standard of care in managing known MG patients includes vigilant monitoring of respiratory function during exacerbations, typically using bedside forced vital capacity (FVC) and negative inspiratory force (NIF) measurements. A declining FVC below 20 mL/kg or NIF weaker than -30 cmH2O warrants consideration of elective intubation and crisis management. The well-known "20/30/40 rule" — FVC less than 20 mL/kg, NIF weaker than -30 cmH2O, or greater than 30% decline from baseline in either measure — is widely taught as a threshold for intervention. Failure to obtain these measurements during an MG exacerbation, or failure to act on values that cross these thresholds, constitutes a clear departure from accepted practice.
Medication-triggered myasthenic crisis deserves particular attention in litigation. A substantial body of literature documents medications that can precipitate or worsen myasthenic weakness. Fluoroquinolone antibiotics (ciprofloxacin, levofloxacin, moxifloxacin), aminoglycoside antibiotics (gentamicin, tobramycin), certain cardiac medications (beta-blockers, procainamide, quinidine), and magnesium sulfate all carry well-documented risks. The Myasthenia Gravis Foundation of America publishes a widely available list of medications to avoid, and prescribing a contraindicated medication to a patient with known MG — or failing to check for MG before administering a high-risk drug in a susceptible patient — is a well-recognized basis for liability.
Treatment Failures and Immunosuppressive Management
Beyond the acute management of crisis, myasthenia gravis requires long-term immunomodulatory therapy in most patients with generalized disease. The treatment paradigm follows a well-established algorithm: acetylcholinesterase inhibitors (typically pyridostigmine) for symptomatic relief, corticosteroids for initial immunosuppression, and steroid-sparing agents such as azathioprine, mycophenolate mofetil, or rituximab for long-term disease control. Thymectomy is indicated for patients with thymoma and is beneficial in non-thymomatous AChR-positive generalized MG, as demonstrated by the landmark MGTX trial published in the New England Journal of Medicine.
Treatment failure malpractice claims in MG typically arise when a physician manages the patient with symptomatic therapy alone (pyridostigmine) without initiating immunosuppressive treatment despite persistent or worsening generalized disease. This approach fails to address the underlying autoimmune pathophysiology and leaves the patient at ongoing risk for crisis and progressive disability. Another common failure involves inadequate monitoring of immunosuppressive therapy — azathioprine requires monitoring of complete blood counts and liver function, mycophenolate requires monitoring for cytopenias and infection, and corticosteroids require attention to the well-known complications of chronic use including osteoporosis, diabetes, and opportunistic infection.
The failure to recommend thymectomy in an appropriate candidate — a patient under 65 with generalized AChR-positive MG who has not responded adequately to initial immunotherapy — can also form the basis of a malpractice claim, particularly when the patient subsequently experiences a crisis that might have been prevented by earlier surgical intervention.
An important nuance for attorneys evaluating MG treatment claims is the distinction between treatment failure and treatment negligence. Myasthenia gravis is a heterogeneous disease, and not all patients respond to first-line therapies. The question in litigation is not whether the patient improved, but whether the physician followed an accepted treatment algorithm, monitored the patient's response appropriately, and escalated therapy when the initial regimen proved inadequate. A physician who tries pyridostigmine, adds corticosteroids, initiates a steroid-sparing agent, monitors the patient's respiratory and functional status, and escalates to plasma exchange or IVIG when acute deterioration occurs has met the standard of care — even if the patient's disease proves refractory. The liability attaches when the physician fails to advance through the established treatment algorithm despite evidence of inadequate disease control.
Distinguishing Myasthenic Crisis from Cholinergic Crisis
A critically important clinical distinction in MG litigation is the difference between myasthenic crisis and cholinergic crisis. Myasthenic crisis results from inadequate neuromuscular transmission — the disease is insufficiently treated, and the patient weakens. Cholinergic crisis results from excessive acetylcholinesterase inhibitor medication (too much pyridostigmine), which paradoxically produces weakness by overstimulating the neuromuscular junction, along with muscarinic side effects such as salivation, lacrimation, urination, diarrhea, miosis, and bradycardia (the SLUDM-BB mnemonic).
Misidentifying the type of crisis leads to precisely the wrong treatment: a patient in myasthenic crisis who is mistakenly treated as cholinergic (by withholding pyridostigmine and delaying immunotherapy) will continue to deteriorate, and a patient in cholinergic crisis who receives additional pyridostigmine will worsen. The standard of care requires distinguishing these two entities through clinical assessment, and in ambiguous cases, through an edrophonium (Tensilon) test or empirical reduction of cholinesterase inhibitors with close monitoring.
In modern practice, cholinergic crisis has become less common due to improved immunosuppressive management and lower reliance on high-dose pyridostigmine. However, it remains a testable clinical scenario and a recognized pitfall in emergency department management. An expert reviewing a crisis case will assess whether the treating physicians correctly identified the crisis type and initiated the appropriate intervention.
Damages Analysis in Myasthenia Gravis Cases
The damages framework in MG malpractice cases depends on the specific failure and its consequences. For delayed diagnosis claims, the damages analysis focuses on the disease progression and complications that occurred during the period of diagnostic delay — including the risk that the patient experienced a preventable myasthenic crisis, underwent unnecessary and invasive testing for incorrect diagnoses, suffered psychological harm from diagnostic uncertainty, or experienced functional decline that might have been prevented or mitigated with earlier treatment.
For crisis-related claims, the damages are often severe. Patients who survive myasthenic crisis after a preventable delay in treatment frequently experience prolonged mechanical ventilation with associated complications (ventilator-associated pneumonia, tracheal injury, ICU-acquired weakness), prolonged hospitalization with associated deconditioning, and long-term psychological sequelae including post-traumatic stress disorder and anxiety related to the ICU experience. Some patients require tracheostomy, and a subset develop chronic respiratory insufficiency requiring long-term ventilatory support.
For medication-triggered crisis claims, the damages analysis must establish the causal link between the offending medication and the crisis, quantify the additional morbidity attributable to the medication-triggered exacerbation, and account for the baseline trajectory of the patient's MG — acknowledging that the disease carries inherent risks while demonstrating that the specific crisis was precipitated by an avoidable prescribing error.
Life-care planning in MG cases should account for the chronic nature of the disease, the cost of ongoing immunosuppressive therapy (which may include expensive biologic agents such as eculizumab or ravulizumab for refractory disease), the need for ongoing neurology follow-up, the risk of future exacerbations, and the functional limitations imposed by residual weakness. Vocational experts should understand that MG-related fatigue and fluctuating weakness can be profoundly disabling even when the patient appears normal at rest — a fact that is often underappreciated by non-neurologist evaluators and one that a neurology expert can articulate effectively for a jury.
How NLC Approaches Myasthenia Gravis Cases
At Neurology Legal Consulting, we understand that myasthenia gravis cases require expert testimony from physicians who diagnose and treat MG in current clinical practice and who can communicate the nuances of neuromuscular junction disease to legal audiences. MG is one of the most evidence-based areas in neurology, with well-established diagnostic criteria, published treatment algorithms, and landmark clinical trials that define the standard of care. This makes it an area where expert opinions must be grounded in the specific published literature and clinical guidelines — and where superficial or outdated opinions will not withstand Daubert scrutiny or effective cross-examination.
NLC connects attorneys with clinically active neurologists and neuromuscular specialists who evaluate MG patients as part of their regular practice, who are current with the evolving treatment landscape including newer biologic therapies, and who have experience with both crisis management and long-term disease optimization. Our experts can address the full spectrum of MG litigation issues, from diagnostic delay and prescribing errors to crisis management failures and long-term treatment planning disputes.
Our case review process for MG matters includes a detailed reconstruction of the diagnostic timeline from initial symptom presentation through definitive diagnosis, analysis of serological and electrodiagnostic testing decisions and their timing, evaluation of the treatment algorithm followed by the managing physician, identification of medication exposures that may have triggered or worsened the patient's disease, and assessment of crisis management decisions including respiratory monitoring, intubation timing, and initiation of immunotherapy.
For cases involving medication-triggered exacerbations, our experts can identify the specific pharmacological mechanism by which the offending drug impairs neuromuscular transmission, cite the published literature documenting the risk, and establish whether the prescribing physician should have known about the contraindication given the patient's documented medical history. For cases involving delayed thymectomy, our experts can reference the MGTX trial data and current consensus guidelines to establish whether earlier surgical intervention would have altered the patient's disease trajectory.
Whether the case involves a missed diagnosis in the emergency department, an outpatient management failure leading to preventable crisis, a prescribing error that triggered respiratory failure, or a dispute over the adequacy of long-term immunosuppressive management, NLC provides expert support that is clinically current, methodologically rigorous, and trial-ready.
This post is for informational purposes and does not constitute legal advice. Standards vary by jurisdiction.